LIM domain only 4 (LMO4), a member of the LIM-only family of transcriptional coregulatory proteins, consists of two LIM protein-protein interaction domains that enable it to function as a linker protein in multiprotein complexes. Here, we have identified estrogen receptor A (ERA) and its corepressor, metastasis tumor antigen 1 (MTA1), as two novel binding partners of LMO4. Interestingly, LMO4 exhibited binding with both ERA and MTA1 and existed as a complex with ERA, MTA1, and histone deacetylases (HDAC), implying that LMO4 was a component of the MTA1 corepressor complex. Consistent with this notion, LMO4 overexpression repressed ERA transactivation functions in an HDAC-dependent manner. Accordingly, silencing of endogenous LMO4 expression resulted in a significant increased recruitment of ERA to target gene chromatin, stimulation of ERA transactivation activity, and enhanced expression of ERA-regulated genes. These findings suggested that LMO4 was an integral part of the molecular machinery involved in the negative regulation of ERA transactivation function in breast cells. Because LMO4 is up-regulated in human breast cancers, repression of ERA transactivation functions by LMO4 might contribute to the process of breast cancer progression by allowing the development of ERA-negative phenotypes, leading to increased aggressiveness of breast cancer cells. (Cancer Res 2005; 65(22): 10594-601) 
Introduction
The LIM-only subclass of LIM proteins is a family of nuclear transcription coregulators that are characterized by the exclusive presence of two tandem LIM domains and no other functional domains. Each LIM domain has two cysteine-rich zinc finger motifs that are involved in protein-protein interactions but have no direct DNA-binding properties (reviewed in refs. 1, 2). These proteins regulate gene transcription by functioning as ''linker'' or ''scaffolding'' proteins by virtue of their LIM domains and are involved in the formation of multiprotein complexes of DNA-binding factors and transcriptional regulatory proteins. Four members of the LIM-only family [LIM domain only 1 (LMO1) to LMO4] have been identified to date. These proteins have been shown to play important roles in cell fate determination, tissue patterning, and organ development. As might be expected, their deregulated expression has been implicated in oncogenesis. LMO1 and LMO2 genes were discovered as oncogenes and are deregulated in acute T-cell lymphocytic leukemia (3) (4) (5) . LMO2 is an obligate regulator of hematopoiesis and angiogenesis (6, 7) and blocks the terminal differentiation of hematopoetic cells when overexpressed (8) . LMO3 was discovered on the basis of sequence homology and nothing much was known regarding its biological and pathologic significance. Recently, it was found that LMO3 interacts with neural transcription factor HEN2 and functions as an oncogene in nueroblastoma, where the expression level of both LMO3 and HEN2 genes was high and associated with poor prognosis (9) .
LMO4 was the latest addition to this family and isolated as an interacting protein of Ldb1/NLI/CLIM and also identified in an expression screen with autologous serum of breast cancer patients (10) (11) (12) (13) . It has 165 amino acid residues and shares only f50% amino acid sequence homology with the LIM domain regions of LMO1, LMO2, and LMO3; thus, it is considered the most distant relative of the family (11) . It has a very broad spectrum of expression in human tissue (13) . In mice, targeted disruption of LMO4 led to defects in neural tube closure, sphenoid bone formation, and altered anterior-posterior patterning (14, 15) , revealing its importance in cell patterning and embryogenesis. Its expression is developmentally regulated in the mammary gland and overexpression blocks the differentiation of mammary epithelial cells (16) . LMO4 is overexpressed in 50% of primary breast tumors (16) , in squamous cell carcinomas of the oral cavity (17) , and in primary prostate cancer (18) , implicating it as an oncogene. It has been identified as a binding partner and a participant in multiprotein complexes with several transcriptional regulatory proteins, such as HEN1, deformed epidermal autoregulatory factor 1 (DEAF1), and BRCA1 (10) (11) (12) (13) (14) (15) (16) . HEN1 (also known as NSCL1/NHLH1) is a basic helix-loop-helix protein. It functions as a transcriptional activator important in hematopoiesis and is specifically expressed in the developing nervous system (19) . LMO2 and LMO4 were found to be binding partners of HEN1 by yeast two-hybrid analysis, but LMO4 and not LMO2 was found to be a repressor of its transcriptional activating functions (20) . LMO4 was found to physically interact with CtBP-interacting protein and the breast and ovarian tumor suppressor protein BRCA1 (21) . This study showed that LMO4 represses BRCA1-mediated transcriptional activation in yeast and mammalian cells but the mechanism of repression was not established (21) . LMO4 also interacts with the coregulatory proteins Clim-2/ldb-1/NL1 and DEAF1 in the same complex. DEAF1 is a DNA-binding protein that interacts with regulatory sequences and modulates transcriptional outcome (12) . Providing additional implication of the role of LMO4 in breast carcinogenesis, it was shown in a recent study that overexpression of LMO4 in mice under the control of the mouse mammary tumor virus induced mammary hyperplasia and mammary intraepithelial neoplasia in two transgenic strains (22) .
Estrogen receptors (ER) are ligand-dependent transcription factors that control a variety of essential physiologic and developmental processes in humans. The nuclear receptors primarily regulate the initiation of transcription by directly binding to specific DNA sequences in the regulatory region of target genes called hormone response elements and recruiting diverse ancillary factors characterized as coregulators along with the basal transcriptional machinery (23) . Ligand binding results in the dismissal of histone deacetylase (HDAC)-containing corepressor complexes and the concomitant recruitment of coactivator complexes. One of such corepressors of ERa is the metastasis tumor antigen 1 (MTA1), a component of nuclear remodeling complex (24) . It functions by recruiting HDACs, which deacetylate histones and subsequently facilitate the compaction of chromatin and transcriptional repression.
In the present study, we have identified LMO4 as a potent repressor of transcriptional activity of ERa. We have also identified ERa and its corepressor protein, MTA1, as LMO4 binding partners and established that a multiprotein complex of LMO4, ERa, MTA1, and HDACs existed in vivo. LMO4 was found to be an important component of the MTA1 corepressor complex and to negatively regulate the expression of the endogenous ERa target genes in a physiologic setting. The potential implications of these regulatory interactions and a role for LMO4 in modulating ERa functions in breast cancer cells are presented.
Materials and Methods
Cell culture and reagents. Human breast cancer cells were cultured in DMEM/F-12 medium supplemented with 10% fetal bovine serum (FBS). For estrogen treatment experiments, cells were grown in dextran-charcoalstripped medium containing 5% charcoal-stripped FBS. Antibodies against the T7 tag were from Bethyl Laboratories (Montgomery, TX); anti-ERa was from Chemicon Inc. (Pittsburgh, PA); and anti-MTA1, HDAC1, and HDAC2 were from Santa Cruz (Santa Cruz, CA). Antimouse and antirabbit horseradish peroxidase or alkaline phosphatase-conjugated antibodies were from Amersham Biosciences (Piscataway, NJ).
Glutathione S-transferase pull-down assay. In vitro transcription and translation of MTA1s, MTA1, LMO4, and ERa was done using a T7-TNT kit (Promega Biosciences, San Luis Obispo, CA), where 1 Ag cDNA in pcDNA 3.1 vector was translated in the presence of [
35 S]methionine in a reaction volume of 50 AL. The reaction mixture was diluted to 1 mL with NP40 lysis buffer (25 mmol/L Tris, 50 mmol/L NaCl, and 1% NP40). An equal aliquot was used for each glutathione S-transferase (GST) pull-down assay. Translation and product size were verified by subjecting 2 AL of the reaction mixture to SDS-PAGE and autoradiography. The GST pull-down assays were done by incubating equal amounts of GST, GST-tagged fulllength proteins, and GST-tagged deletion constructs immobilized on glutathione Sepharose beads (Amersham Biosciences) with in vitro translated 35 S-labeled protein to which the binding was being tested. Bound proteins were isolated by incubating the mixture for 3 hours at 4jC, washing five times with NP40 lysis buffer, eluting the proteins with 2Â SDS buffer, and separating them by SDS-PAGE. The bound proteins were then visualized by autoradiography.
Immunoprecipitation and immunoblotting. Cell extracts for immunoprecipitation were prepared by washing cells thrice with PBS. Cells were then lysed using a minimum volume of high-salt lysis buffer [50 mmol/L Tris-HCl (pH 7.5), 500 mmol/L NaCl, 100 mmol/L NaF, 200 mmol/L NaVO 5 , 1 mmol/L phenylmethylsulfonyl fluoride, and protease inhibitor cocktail (Life Technologies, Gaithersburg, MD)] for 15 minutes at À80jC and 15 minutes on ice to freeze and thaw the cells to aid lysis. Lysates were centrifuged in an Eppendorf centrifuge at 4jC for 15 minutes. Lysates were diluted with 1 mL lysis buffer without added NaCl and immunoprecipitation was done for 3 hours at 4jC using 1 Ag of antibody per milligram of protein. For immunoblotting, the immunoprecipitated proteins were resolved on a 10% SDS-PAGE gel, transferred to nitrocellulose membrane, and probed with appropriate antibodies.
Immunofluorescence and confocal microscopy studies. We determined the cellular localization of proteins by indirect immunofluorescence as described (24) . Briefly, cells grown on glass coverslips were fixed in 4% phosphate-buffered paraformaldehyde for 15 minutes. Cells were permeabilized in methanol at À20jC for 4 minutes. Following permeabilization, cells were incubated with primary antibodies for 2 hours at room temperature, washed thrice in PBS, and then incubated with secondary antibodies conjugated with 546-Alexa (red) or 488-Alexa (green) from Molecular Probes (Eugene, OR). The DNA dye Topro-3 (Molecular Probes) was used for nuclear localization (blue). Confocal scanning analysis was done using an Olympus FV300 laser scanning confocal microscope in accordance with established methods using sequential laser excitation to minimize the possibility of fluorescence emission bleed through. Each image is a three-dimensional reconstructed stack of serial Z sections at the same cellular level and magnification. Colocalization of two proteins is shown yellow for red and green fluorescence.
Transfection and promoter assays. Cells were maintained in DMEM/ F-12 (1:1) supplemented with 10% FCS. For reporter assays, the required plasmids were transiently transfected using FUGENE6 kit from Roche Biochemicals (Indianapolis, IN) as per instructions of the manufacturer. Cells were cotransfected with h-galactosidase and luciferase assay was done using Luciferase assay kit (Promega).
RNA interference transfection and reverse transcription-PCR analysis. RNA interference (RNAi) transfections were done using Oligofect-AMINE (Invitrogen) according to the protocol of the manufacturer. RNAi against LMO4 was purchased from Qiagen. A pool of four individual RNAi was used and the sequences have been provided below. Forty-eight hours were allowed to elapse after transfection to allow efficient silencing of the gene. Reverse transcription-PCR (RT-PCR) was done using Access RT-PCR kit (Promega) using specific primers shown below: LMO4 RNAi 1: 5V -ACGUCCUGUUACACCAAAAUU-3V . LMO4 RNAi 2: 5V -CAUGAUCCUUUGCAGAAAUUU-3V . LMO4 RNAi: 5V -CGCAAGGCAAUGUGUGUAUCAUU-3V . LMO4 RNAi 4: 5V -CUACAUCCAUGGCSGUUUAUU-3V . LMO4: 5V -GGACCGCTTTCTGCTCTATG-3Vand 5V -ACGAGTTCACTCGCAGGAAT-3V . pS2: 5V -ATACCATCGACGTCCCTCCA-3Vand 5V -AAGCGTGTCTGAGGTGTCCG-3V . Total progesterone receptor (PR): 5V -CAAATGAAAGCCAAGCCCTA-3V
and 5-TGCCTCTCGCCTAGTTGATT-3V . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH):
5V -CCATCTTCCAGGAGCGAGATC-3Vand 5V -CGTTCAGCTCAGGGATGACC-3V .
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation assay was done in MCF-7 cells following the procedure as described elsewhere (24) . Briefly, LMO4 expression in MCF-7 cells was silenced using RNAi against LMO4. Cells were later cultured in dextran-charcoal-stripped medium for 24 hours, treated with estrogen (10 À9 mol/L) for 1 hour, and cross-linked with 1% formaldehyde. Cells were lysed by sonication and chromatin immunoprecipitation was done with an ERa-specific antibody. Immunoprecipitated DNA fragments were analyzed for pS2 chromatin by amplifying specific region by PCR using pS2 chromatin-specific primers with the following sequence: 5V -GAATTAGCTTAGGCCTAGACGGAATG-3V and 5V -AGGATTTGCTGATAGGACAGAG-3V . Silencing of LIM domain only 4 expression in metastasis tumor antigen 1 stable clones and Northern blotting. MTA1-overexpressing cells were transfected with LMO4-specific RNAi. After 24 hours, cells were maintained for 24 hours in dextran-charcoal-stripped medium and later treated with estrogen (10 -9 mol/L) for 16 hours. Total RNA from the cells was extracted, resolved on an RNA gel, and blotted onto a nitrocellulose membrane. Levels of specific mRNAs were analyzed by probing the blot with appropriate radiolabeled probes and were measured by autoradiography. Fig. 1A and B) . LMO4 overexpression in both cell lines led to a distinct repression of ERE transcription activity independent of estrogen stimulation, with a 3-fold repression in MCF-7 cells and a 2-fold repression in ZR-75 cells. To further validate the observed repression of ERa transactivation by LMO4, we examined the effects of increased amounts of LMO4 plasmid on ERE-luciferase transcription in MCF7 cells (Fig. 1C) . As little as 250 ng of LMO4 was found to be sufficient to exert a potent repression of ER transactivation function in breast cancer cells and the extent of repression increased with increasing amount of LMO4 expression in the cells.
LIM domain only 4 represses estrogen receptor A transactivation in a histone deacetylase-dependent manner. To test the possibility that the repression of ERa functions by LMO4 could be HDAC dependent, we examined the effect of trichostatin A, a specific inhibitor of HDACs, on LMO4-induced repression of ERE transcription in both MCF-7 and ZR-75 cells ( Fig. 2A) . We found that LMO4-mediated repression of ERa transactivation activity could be effectively relieved by inhibiting HDAC activity. These results suggest that LMO4 requires functional HDACs for its noticed corepressor function of ERa activity.
We have previously reported that MTA1, a component of the NURD complex, functioned as a corepressor of ERa transactivation functions by binding and recruiting HDACs to the repressor complex (24) . To see if LMO4 may be functioning via this MTA1 corepressor complex, we tested the effect of silencing LMO4 expression using LMO4-specific RNAi on MTA1 repression of ERa transactivation function in MCF-7 cells. As expected, overexpression of MTA1 effectively repressed ER transactivation functions. However, silencing of LMO4 expression resulted in a >3-fold enhancement of the ERE-luciferase activity, demonstrating that the repression of ERa transactivation functions was released on knocking down LMO4 expression (Fig. 2B ) both with and without MTA1 overexpression. These findings suggest that LMO4 might be an essential component of the MTA1 corepressor complex.
We next tested whether LMO4-mediated repression was dependent on MTA1. Results indicate that the LMO4-induced repression of ERE-luciferase activity was partially relieved by cotransfection of MTA1-specific RNAi (Fig. 2C) . These assays showed that, functionally, LMO4 and MTA1 corepressor functions were interlinked and that LMO4 could be a part of the MTA1 corepressor complex. These observations suggested an inherent role of the endogenous LMO4 in influencing the status of ERa transactivation function and that LMO4 may also be important in the corepressor activity of MTA1 in breast cancer cells.
LIM domain only 4 binds to metastasis tumor antigen 1. To test whether LMO4 could physically interact with MTA1, in vitro binding studies were done using 35 S-labeled full-length LMO4 and GST-tagged full-length MTA1 and GST-MTA1 deletion constructs. Results indicated that LMO4 binds with the full-length MTA1 (Fig. 3A) . Full-length LMO4 bound to both the NH 2 -terminal BAH and ELM domains of MTA1 (Fig. 3A, deletion construct A) as well as the COOH-terminal region (deletion construct D) of MTA1, encompassing the Src homology 2 (SH2)-and SH3-binding domains (Fig. 3A) . Binding studies of 35 S-labeled MTA1 with GST-tagged fulllength LMO4 and its deletion constructs showed that the first LIM domain (LIM1, amino acids 20-89) of LMO4 was sufficient to bind 35 S-labeled MTA1 (Fig. 3B, deletion construct B) . Weak or no binding was observed between the MTA1 and the second LIM domain of LMO4. This bidirectional in vitro binding study showed that MTA1 and LMO4 were binding partners and strengthened the possibility that LMO4 could be a part of the MTA1 corepressor complex.
LIM domain only 4 also interacts with estrogen receptor A and histone deacetylase but not estrogen receptor B. Because LMO4 has been shown to be up-regulated in malignant breast cancers that were, in general, functionally ERa negative, and because MTA1 functions as a corepressor of ERa transcriptional functions (24), we next investigated the possibility that LMO4 directly interacted with ERa. Indeed, 35 S-labeled ERa interacted with GST-tagged full-length LMO4 in vitro (Fig. 4A) . Binding studies using the individual GST-tagged domains of LMO4 with full-length 35 S-labeled ERa showed that the first LIM domain of LMO4 along with additional NH 2 -terminal region (Fig 4A, deletion (Fig. 4B) . No binding was observed with the activation function-1 domain (Fig. 3B , deletion constructs A and B, amino acids 1-180). We also tested the in vitro binding of LMO4 to HDAC2, which is an important component of the MTA1 corepressor complex (24) . GST-tagged HDAC2 clearly showed binding affinity to 35 S-labeled LMO4 in vitro (Fig. 4C) . In addition to being a binding partner of ERa, we wanted to know whether LMO4 could also interact with ERh. To address this question, we have done an in vitro binding experiment using 35 S-labeled in vitro translated ERh to GST-tagged full-length LMO4. No binding of LMO4 to ERh was observed, indicating that LMO4 is likely a specific binding partner of ERa. The experiment was repeated twice for confirmation (Fig. 4D) . Overall, this series of in vitro binding studies showed that LMO4 strongly interacts with the three integral components of the ERa-MTA1 corepressor complex, namely, ERa, MTA1, and HDACs.
LIM domain only 4 is a component of metastasis tumor antigen 1 corepressor complex. To confirm the binding of LMO4 with ERa and MTA1 in vivo, we did coimmunoprecipitation followed by Western blot analysis. Due to lack of a commercial antibody for LMO4 suitable for immunoprecipitation or Western immunoblotting of endogenous protein, we transfected MCF-7 cells with an expression vector of T7-tagged LMO4. Results indicate that immunoprecipitated T7-tagged LMO4 was present in the same multiprotein complex as ERa and MTA1 (Fig. 5A ). Because MTA1 functions as a corepressor by recruiting HDACs (24), we next tested whether HDACs were also an integral part of the LMO4 and MTA1 complex. MCF-7 cells were transfected with Myc-tagged LMO4. Cell lysates were immunoprecipitated with anti-Myc antibody and analyzed for the presence of HDACs among the LMO4-associated endogenous proteins. Both HDAC1 and HDAC2 were immunoprecipitated along with LMO4 and MTA1 (Fig. 5B) , demonstrating that LMO4 was a part of the MTA1 corepressor complex. These findings suggested that LMO4 may repress the ER transactivation function as an integral component of HDAC-containing corepressor complexes.
LIM domain only 4 colocalizes with metastasis tumor antigen 1 and estrogen receptor A in breast cancer cells. To confirm the protein-protein interactions between LMO4, MTA1, and ERa in situ, we next examined whether Myc-LMO4 colocalizes with the endogenous MTA1 and ERa in MCF-7 cells. Immunofluorescence studies indicated that LMO4 colocalizes individually with both MTA1 and ERa predominantly in the cell nucleus. Overlap of red and green fluorescence resulted in the yellow spots ( Fig. 5D and E, G and H) , representing colocalization. Some LMO4 was also localized to the cytoplasm; however, such localization of LMO4 did not noticeably change in either serum-starved or estrogen-deprived MCF7 cells (data not shown). Together, these experiments confirmed MTA1 and ERa as new binding partners of LMO4.
LIM domain only 4 is a natural inhibitor of endogenous estrogen receptor A functions. To determine whether LMO4 could negatively regulate ERa transactivation functions in a physiologic context, we investigated changes in the expression level of the endogenous ERa target genes with knockdown of LMO4 expression in MCF-7 cells. Treatment of cells with LMO4-specific RNAi enhanced the level of pS2 mRNA by >2-fold when compared with cells treated with control RNAi (Fig. 6A, second  panel) . We also did RT-PCR analysis of another ER-regulated gene (i.e., PR) in cells transfected with control RNAi or LMO4-specific RNAi. Results indicate that RNAi-mediated down regulation of LMO4 expression increased total PR expression levels at least 2-fold (Fig. 6A, third panel) . To further validate these results, we used Northern blot analysis of estrogen-responsive genes in MTA1-overexpressing stable cell lines. As expected from the earlier data, the expression levels in these stable clones were considerably repressed by overexpression of MTA1 when compared with the parental cells (24) . Interestingly, knockdown of LMO4 expression led to a marked increase of pS2 mRNA levels (Fig. 6B) . These data indicated that by decreasing the level of LMO4 expression, MTA1-induced repression of estrogen-responsive genes was relieved. Thus, LMO4 may be a functionally essential component of the MTA1 corepressor complex.
Silencing of LIM domain only 4 expression promotes estrogen receptor A recruitment to its target chromatin. To gain further insight into the observed negative regulatory function of LMO4 in relation to ERa-regulated genes, we next investigated whether the levels of the endogenous LMO4 also affected the recruitment of ERa to its target gene chromatin. To test this possibility, we examined the effect of silencing of LMO4 expression by LMO4 RNAi upon the ability of ERa to interact with the pS2 gene chromatin by chromatin immunoprecipitation assay in MCF-7 cells. On estrogen treatment, the level of recruitment of ERa to the pS2 gene chromatin was 2-fold higher in cells treated with LMO4 RNAi when compared with cells with control RNAi (Fig. 6C) , clearly showing that silencing of LMO4 expression increased the recruitment of ER to its target genes. Together, these results clearly showed that LMO4 may be an endogenous regulator of ERa transactivation activity and functions in breast cancer cells, and up-regulation of LMO4 as has been observed in human breast cancer may lead to inhibition of ERa-transcriptional responsiveness.
Discussion
LMO4 is overexpressed in 50% of primary breast tumors and its enhanced expression blocks mammary gland differentiation. At the mechanistic level, very little is known regarding the mode of LMO4 functioning, LMO4 interacting molecular partners, or of the signaling pathways affected by LMO4 through which its effects in the breast cancer cells are manifested. In this context, we sought to investigate the effects of LMO4 upon estrogen signaling and functioning by focusing on key proteins of breast cancer tumorigenesis, such as the ERa and its coregulatory proteins. Preliminary ERE-luciferase assays conducted in MCF-7 and ZR-75 cell lines showed that LMO4 might be functioning as a negative regulator of ERa transactivation functions (Fig. 1) . The LMO4-induced repression of ERE-luciferase could be reversed or relieved by trichostatin A, which is a specific inhibitor of HDACs ( Fig. 2A) in both MCF-7 and ZR-75 cell lines. These data clearly showed that the repression exhibited by LMO4 was HDAC dependent. Studies from our laboratory had identified MTA1 as an ERa corepressor. MTA1 is a part of the NURD complex and functions by recruiting HDACs, which are a class of enzymes involved in deacetylation of hyperacetylated histone tails, leading to compaction of chromatin and transcriptional repression (25) .
Because both LMO4 are MTA1 are predominantly nuclear coregulatory proteins, our results prompted us to check whether the repression of ERa by MTA1 and the repression by LMO4 were interrelated. Silencing of LMO4 repression resulted in the relieving of MTA1-induced repression of ERa functions (Fig. 2B) and silencing of MTA1 expression partially relieved LMO4-induced ERa repression (Fig. 2C) . These data showed that the functions of these two proteins were interlinked and raised the possibility of LMO4 physically participating in the MTA1 corepressor complex. A series of different in vitro binding studies established that ERa, MTA1, and HDACs are novel binding partners of LMO4. The in vitro binding results were confirmed in vivo with T7-LMO4 interacting with both ERa and MTA1 (Fig. 5A) . We also showed that transfected Myc-LMO4 could also be coimmunoprecipitated along with MTA1, HDAC1, and HDAC2 (Fig. 5B) . Colocalization studies lent further support to the notion that LMO4 was a part of an MTA1 corepressor complex in vivo.
LIM domains are exclusively involved in protein-protein interactions. LMO4, with two tandem LIM domains with a capability of individually interacting with ERa, MTA1 and HDACs, may be playing the role of a ''linker'' or ''scaffolding'' protein involved in stabilizing the corepressor complex. In the same context, a recent study showed that LMO4 associated with glycoprotein 130 (gp130) subunit, a common receptor subunit for interleukin (IL)-6 type cytokines, and functioned as a part of the gp130 complex. Overexpression of LMO4 enhanced the transcription of IL-6 target genes like Stat3, whereas silencing of LMO4 expression by RNAi led to a decrease of transcription of IL-6 target genes, implying the function of LMO4 as a scaffolding protein in the stabilization of gp130 complex (26) .
Silencing of LMO4 expression in cells with LMO4 RNAi led to a drastic increase of ERE transcription as measured by EREluciferase functional assay (Fig. 2) and this raised the possibility that LMO4 could act as a natural negative regulator of ERa pathway. Indeed, we discovered that down-regulation of LMO4 increased expression of estrogen-responsive genes pS2 and PR and also stimulated the recruitment of ERa to the endogenous pS2 gene chromatin (Fig. 6) . Together, these findings established that LMO4 is a potent endogenous repressor of ERa transactivation function and that the levels of endogenous LMO4 may influence the status of ERa functions in breast cancer cells. In addition, there was also partial relieving of LMO4-induced repression of ERE transcription with MTA1 knockdown (Fig. 2C) , suggesting the possibility of potential involvement of additional corepressors in the noted corepressor function of LMO4. This, we believe, would open new avenues of study directed toward recognizing other ERcorepressor complexes of which LMO4 might be an integral part.
MTA1 is expressed virtually in all human cell lines and overexpressed in breast, ovarian, lung, gastric, colorectal, and pancreatic cancers. The level of MTA1 in rapidly growing breast cancer cells was found to be twice that in the normal epithelial cells (27) . It functions as a part of HDAC or nucleasome remodeling complexes and acts as a major modulator of transcription. MTA1 was found to be a potent repressor of ERE transcription and overexpression of MTA1 in breast cancer cells enhanced the ability of cells to invade and grow in an anchorage-independent manner, implicating its role in metastatic potential of cells. Heregulin also promoted the interaction of MTA1 with ER (24) . In addition, MTA1 expression could also be induced by the growth factor Heregulin, a ligand for HER3 and HER4, which is also frequently deregulated in human epithelial cancers (24) . Incidentally, it has also been reported that the expression of LMO4 is also significantly upregulated by Heregulin treatment (28) . Indeed, breast cancer cell lines that highly express MTA1, such as MDA-MB-231 (29), BT474, and T47D (28), also express high levels of LMO4 (28) . In addition, down-regulation of LMO4 expression in MDA-MB-231 cells, an invasive breast cancer cell line, resulted in 3-to 4-fold decrease in cell motility and a 2-fold decrease in cell invasion. Overexpression of LMO4 in MCF-10A, which is a normal breast epithelial cell line, resulted in a 3-fold increase in cell migration and 2-fold increase in cell invasion (22) . Overexpression of MTA1 in MCF-7 breast cancer cell line also had an identical effect of increased cell invasiveness and anchorage-independent growth (24) . Up-regulation of both MTA1 and LMO4 genes by a common signal (i.e., Heregulin) enhanced expression of these proteins in common breast cancer cell lines. Similar phenotypic changes resulting from overexpression all strongly support the notion of functional synergy between MTA1 and LMO4.
To summarize, in the present study, we have identified ERa and MTA1 as two novel binding partners of LMO4 in a physiologically relevant context and that LMO4 functions as an integral part of the MTA1 corepressor complex. LMO4 effectively repressed ERa transactivation functions in an HDAC-dependent manner. Downregulation of LMO4 expression resulted in a significant enhancement of ERa functions. Because LMO4 is overexpressed in 50% of breast tumors and not much is known regarding the mechanistic role played by it at the molecular level as an oncogenic protein, Figure 5 . LMO4 forms a part of MTA1 corepressor complex in vivo and colocalizes with MTA1 and ERa in the nucleus. A, MCF-7 cells were transfected with expression constructs encoding T7-tagged LMO4. After 48 hours, cell lysate was prepared and the T7-tagged LMO4 was immunoprecipitated (IP ) with T7-specific antibody. Immunoblotting was done with anti-T7 antibody (Anti-T7 Ab) and clear bands in Lysate and Anti-T7 Ab lanes (third panel ) showed the expression of T7-LMO4 in the cells and the successful immunoprecipitation of it with anti-T7 antibody, respectively. Immunoblotting with ERa-and MTA1-specific antibodies recognized ERa (second panel, Lysate and Anti-T7 Ab) and MTA1 (first panel, Lysate and Anti-T7 Ab) among the proteins coimmunoprecipitated along with LMO4, exhibiting that LMO4 binds ER and MTA1 in vivo . Absence of these bands in the Control IgG lane (immunoprecipitation with control IgG) proved the specificity of immunoprecipitation and Western blot analysis. B, immunoprecipitation of Myc-tagged LMO4 expressed in MCF-7 cells and subsequent Western blotting showed that HDAC2 (third panel ), HDAC1 (second panel ), and MTA1 (first panel ) were present among the coimmunoprecipitated proteins and proved that LMO4 was a part of MTA1 corepressor complex. C, MCF7 cells were transiently transfected with Myc-LMO4 and 48 hours later were processed as described in Materials and Methods for immunofluorescent localization of Myc-LMO4 (green ), ERa (red ), and DNA (blue ); Cells were examined by confocal microscopy for localization of Myc-LMO4 (green fluorescence ; in C and F ) and colocalization of Myc-LMO4 with ERa and MTA1 (yellow fluorescence ). Distinct yellow spots in the nucleus showed the colocalization of Myc-tagged LMO4 with endogenous ERa (D and E) and with endogenous MTA1 (G and H ), proving them to be LMO4 binding partners in vivo.
our present findings raise the possibility that LMO4 up-regulation might contribute to the process of breast cancer progression by repressing ERa transactivation functions and, consequently, allowing the development of ERa-negative phenotypes, leading to increased aggressiveness and invasiveness of breast cancer cells.
